inhal
corticosteroid
ic
limit
efficaci
reduc
chronic
obstruct
pulmonari
diseas
copd
exacerb
increas
pneumonia
risk
unknown
mechan
rhinovirus
precipit
exacerb
increas
suscept
secondari
bacteri
infect
show
ic
fluticason
propion
fp
impair
innat
acquir
antivir
immun
respons
lead
delay
viru
clearanc
previous
unrecognis
advers
effect
enhanc
mucu
impair
antimicrobi
peptid
secret
increas
pulmonari
bacteri
load
virusinduc
exacerb
exogen
revers
effect
fp
suppress
interferon
may
occur
inhibit
rigi
virussens
pathway
mice
defici
type
receptor
suppress
antimicrobi
peptid
enhanc
mucin
respons
rhinoviru
infect
studi
identifi
type
interferon
central
regul
antibacteri
immun
mucu
product
suppress
interferon
ic
virusinduc
copd
exacerb
like
mediat
pneumonia
risk
rais
suggest
inhal
therapi
may
protect
cute
exacerb
airway
diseas
major
caus
morbid
mortal
rhinovirus
rv
frequent
caus
exacerb
experiment
challeng
studi
asthma
chronic
obstruct
pulmonari
diseas
copd
confirm
causal
role
rv
infect
exacerb
innat
immun
respons
rv
involv
product
type
iii
interferon
ifn
airway
epitheli
immun
cell
ifn
respons
viru
infect
impair
asthma
copd
relat
increas
exacerb
sever
inhal
corticosteroid
ic
frequent
prescrib
therapi
airway
diseas
modestli
reduc
copd
exacerb
frequenc
clinic
trial
report
increas
pneumonia
risk
ic
use
copd
although
mechan
underli
effect
unknown
sever
rv
infect
increas
frequenc
secondari
bacteri
infect
copd
suggest
increas
pneumonia
risk
may
consequ
increas
sever
initi
viru
infect
emerg
evid
suggest
corticosteroid
may
impair
innat
antivir
immun
respons
studi
assess
effect
ic
host
antivir
antibacteri
respons
specif
copd
diseas
associ
insensit
corticosteroid
precis
mechan
includ
role
type
ifn
underli
advers
effect
elucid
use
model
rhinoviru
infect
rhinovirusinduc
copd
exacerb
demonstr
commonli
use
ic
fluticason
propion
fp
impair
innat
acquir
antivir
immun
respons
lead
delay
viru
clearanc
mucu
hypersecret
increas
lung
bacteri
load
studi
highlight
central
role
type
ifn
regul
antimicrobi
immun
mucu
secret
virusinduc
exacerb
advers
effect
associ
immun
suppress
ic
provid
mechan
explain
increas
risk
pneumonia
associ
use
copd
fp
affect
transcript
factor
regul
immun
rv
determin
efficaci
durat
action
ic
mous
model
fp
treatment
assess
glucocorticoid
receptor
gr
activ
measur
nuclear
grdna
bind
administr
fp
dose
similar
employ
previou
anim
studi
significantli
increas
gr
activ
tenfold
lower
dose
fig
rv
infect
activ
immuneregul
transcript
factor
includ
nuclear
factor
kappab
requir
proinflammatori
respons
rv
infect
ifn
regulatori
requir
antivir
respons
assess
effect
fp
administr
fig
rv
activ
transcript
factor
mous
lung
fp
suppress
lung
activ
rvinfect
mice
h
post
infect
fig
activ
rv
occur
h
post
infect
signific
suppress
also
observ
fptreat
mice
fig
ic
suppress
innat
immun
impair
viru
control
next
assess
effect
fp
innat
antivir
immun
respons
rv
infect
mice
fp
suppress
rv
induct
lung
mrna
reduct
respect
fig
bal
protein
reduct
respect
fig
fp
also
suppress
rv
induct
interferonstimul
gene
isg
synthetas
protein
kinas
pkr
viperin
protein
bal
reduct
respect
fig
type
ifn
receptor
signal
requir
airway
natur
killer
nk
cell
respons
rv
reduc
number
total
activ
express
nk
cell
observ
rvinfect
mice
treat
fp
fig
consist
suppress
innat
antivir
respons
fig
fp
treatment
led
delay
viru
clearanc
increas
rv
rna
copi
fptreat
mice
h
post
infect
maxim
effect
size
threefold
h
increas
level
infecti
viru
h
fig
confirm
ic
compound
apart
fp
also
impair
antivir
immun
evalu
effect
anoth
commonli
use
agent
budesonid
rv
infect
mice
administr
budesonid
similarli
suppress
rv
induct
lung
increas
rv
rna
supplementari
fig
fp
impair
adapt
immun
respons
rv
infect
next
determin
effect
fp
adapt
immun
respons
rv
infect
fig
total
activ
number
cell
suppress
fptreat
mice
fig
c
serum
level
rvspecif
antibodi
neutralis
antibodi
fig
fig
suppress
cellular
airway
inflamm
reduc
number
neutrophil
lymphocyt
macrophag
observ
bal
supplementari
fig
fp
also
suppress
rv
induct
bal
neutrophil
chemokin
lymphocyt
chemokin
supplementari
fig
fp
enhanc
mucin
product
rvinfect
mice
evalu
effect
fp
bal
fluid
concentr
mucin
major
glycoprotein
constitu
airway
mucu
rv
infect
alon
increas
airway
product
mucin
glycoprotein
significantli
increas
fp
treatment
fig
fp
impair
antibacteri
respons
rvinfect
mice
evalu
advers
effect
associ
fp
administr
rv
infect
assess
lung
bacteri
load
measur
bacteri
rrna
fp
increas
bacteri
load
rvinfect
mice
fig
fp
also
suppress
rv
induct
secretori
leukoproteas
inhibitor
slpi
protein
reduct
fig
antimicrobi
peptid
amp
implic
protect
secondari
bacteri
infect
follow
rv
infect
copd
fp
administr
also
suppress
rv
induct
proinflammatori
cytokin
tnf
supplementari
fig
amp
effect
rv
induct
amp
mannosebind
supplementari
fig
amp
surfact
proteind
lysozym
significantli
induc
rv
infect
suppress
fp
mice
supplementari
fig
fp
suppress
rigimedi
ifn
respons
investig
mechan
wherebi
fp
suppress
innat
acquir
immun
respons
next
assess
pattern
recognit
receptor
prr
ifn
signal
pathway
inhibit
fp
human
bronchial
epitheli
cell
observ
mice
vivo
fp
treatment
cell
vitro
suppress
rv
induct
fig
activ
prr
rigi
fp
treatment
markedli
suppress
induct
fig
rigi
agonist
fig
effect
agonist
fig
induc
ifn
express
via
adaptor
molecul
tir
domaincontain
adaptor
induc
trif
rigi
signal
via
mitochondri
antivir
signal
protein
mav
therefor
transfect
cell
promoterreport
construct
stimul
use
plasmid
encod
constitut
activ
trif
mav
transfect
significantli
increas
promot
activ
fig
f
consist
find
fp
suppress
rigimedi
ifn
induct
treatment
fp
suppress
promot
activ
fig
f
secondari
amplif
virusinduc
ifn
releas
involv
type
ifn
act
autocrin
manner
via
ifn
alphabeta
receptor
ifnar
stimul
induct
ifn
isg
assess
effect
fp
ifn
signal
stimul
cell
recombin
found
effect
fp
induct
isg
viperin
myxoviru
resist
fig
therebi
demonstr
fp
suppress
ifn
restrict
effect
initi
virussens
pathway
secondari
amplif
via
ifnar
ifn
signal
via
ifnar
induc
phosphoryl
therefor
confirm
find
immunodetect
phosphoryl
phosphoryl
investig
cell
stimul
recombin
fp
effect
induct
either
phosphoryl
fig
addit
confirm
vitro
find
demonstr
fp
administr
effect
lung
isg
induct
follow
recombin
administr
mice
fig
reduc
viru
load
revers
mucin
augment
fp
demonstr
suppress
ifn
fp
function
relat
increas
viru
load
mucin
product
administ
recombin
combin
fp
treatment
rv
infect
fig
clariti
select
experiment
group
fig
full
data
set
supplementari
fig
f
bacteri
copi
number
rrna
lung
tissu
h
measur
quantit
pcr
secretori
leucocyt
proteas
inhibitor
slpi
protein
bal
measur
elisa
figur
except
right
data
repres
mean
fiveeight
mice
per
treatment
group
repres
least
two
independ
experi
data
analys
oneor
twoway
anova
bonferroni
post
test
ns
nonsignific
p
p
p
right
data
point
repres
sera
pool
five
mice
per
group
repres
two
independ
experi
viperin
express
fig
bal
protein
concentr
fig
compar
fptreat
rvinfect
mice
administr
follow
fp
treatment
infect
significantli
reduc
viru
load
level
observ
untreat
virusinfect
mice
fig
treatment
addit
prevent
fp
upregul
bal
glycoprotein
level
fig
revers
fp
impair
antibacteri
immun
secondari
bacteri
infect
rvinduc
copd
exacerb
mediat
virusinduc
neutrophil
elastasemedi
degrad
amp
includ
slpi
therefor
investig
whether
could
prevent
occur
treatment
enhanc
fp
suppress
bal
neutrophil
number
neutrophil
elastas
level
fig
revers
fp
suppress
bal
slpi
level
prevent
fp
augment
bacteri
load
fig
rvinfect
mice
howev
treatment
effect
fp
suppress
antibacteri
mediat
tnf
supplementari
fig
fig
confirm
ifnar
signal
also
import
slpi
product
rv
infect
measur
bal
slpi
protein
rvinfect
mice
observ
reduc
concentr
fig
restor
acquir
respons
reduc
observ
effect
treatment
fp
suppress
adapt
immun
respons
differ
bal
cell
number
serumneutralis
antibodi
level
rvinfect
mice
treat
fp
versu
fp
alon
supplementari
fig
contrast
effect
observ
fig
recombin
also
effect
fp
enhanc
bal
protein
level
supplementari
fig
fp
suppress
ifn
enhanc
mucu
secret
copd
cell
next
investig
whether
similar
advers
effect
fp
occur
cell
copd
patient
evalu
effect
fp
airway
epitheli
cell
aec
sampl
bronchoscop
nine
patient
gold
stage
diseas
cultur
airliquid
interfac
qualiti
cultur
confirm
presenc
ciliat
epithelium
mucusproduc
cell
pseudostratifi
structur
assess
transepitheli
electr
resist
supplementari
fig
demographicclin
characterist
patient
tabl
fp
significantli
suppress
earli
rv
induct
keep
find
fp
administr
augment
mucin
product
respons
rv
infect
mice
also
observ
increas
mucu
stain
associ
fp
treatment
rvinfect
human
copd
aec
n
subject
sampl
avail
histolog
analysi
fig
fp
impair
ifn
respons
copd
exacerb
mous
model
investig
effect
fp
rvinduc
exacerb
copdlik
diseas
vivo
mous
model
rvexacerb
elastaseinduc
emphysema
fig
mani
featur
human
virusinduc
copd
exacerb
recapitul
protein
bal
elastasetr
mice
fig
increas
viru
load
day
post
infect
fig
fp
suppress
rv
induct
bal
total
cell
lymphocyt
signific
effect
neutrophil
fig
fp
also
suppress
rv
induct
lymphocyt
chemokin
bal
fig
addit
suppress
rv
induct
tnf
slpi
fig
g
fp
also
enhanc
rv
induct
bal
protein
fig
mucu
stain
lung
section
fig
signific
effect
bal
protein
level
fig
advers
effect
ic
use
human
copd
exacerb
confirm
clinic
relev
find
measur
antivir
respons
sputum
sampl
cohort
patient
copd
episod
virusinduc
copd
exacerb
occur
rhinoviru
n
coronaviru
n
rsv
n
influenza
n
sampl
assess
patient
suffici
sampl
evalu
clinic
stabil
baselin
exacerb
patient
exacerb
onset
week
exacerb
fig
patient
stratifi
accord
current
use
n
nonus
n
ic
baselin
characterist
subgroup
tabl
ic
user
suppress
baselin
sputum
cell
express
versu
ic
nonus
signific
differ
observ
supplementari
fig
keep
prior
find
vitro
anim
model
ic
user
suppress
sputum
cell
express
exacerb
onset
fig
evalu
mrna
express
foldchang
baselin
also
demonstr
signific
suppress
ic
user
supplementari
fig
current
smoke
affect
antivir
respons
also
carri
subanalysi
exclud
current
smoker
subgroup
ic
user
significantli
suppress
sputum
cell
supplementari
fig
sputum
cell
express
viperin
week
also
significantli
suppress
ic
user
versu
nonus
differ
observ
fig
ic
user
also
suppress
sputum
supernat
protein
concentr
exacerb
onset
fig
enhanc
sputum
glycoprotein
concentr
week
fig
secondari
bacteri
infect
occur
follow
experiment
rv
infect
copd
subject
take
ic
peak
bacteri
load
occur
day
post
rv
infect
determin
ic
use
associ
increas
secondari
bacteri
infect
copd
evalu
bacteri
load
qpcr
similar
time
point
week
postexacerb
onset
found
signific
increas
ic
user
versu
nonus
fig
keep
effect
fp
mice
ic
user
also
suppress
sputum
cell
slpi
express
exacerb
fig
ic
use
virusinduc
copd
exacerb
also
associ
greater
maximum
percentag
declin
baselin
postbronchodil
peak
expiratori
flow
ic
user
versu
ic
nonus
fig
correl
ifn
slpi
exacerb
consist
find
type
ifn
neg
regul
mucin
product
rv
infect
mice
observ
peak
sputum
cell
express
peak
sputum
concentr
protein
neg
correl
sputum
virusinduc
copd
exacerb
fig
similarli
keep
find
mice
interferon
respons
also
involv
slpi
product
viru
infect
found
peak
sputum
cell
express
viperin
posit
correl
slpi
express
fig
use
model
rv
infect
shown
fp
commonli
use
ic
man
suppress
critic
antivir
immun
respons
lead
impair
lung
viru
control
previous
unrecognis
advers
effect
mucin
enhanc
impair
antibacteri
immun
effect
amelior
recombin
administr
thu
relat
ifn
suppress
associ
fp
administr
importantli
show
advers
effect
fp
also
occur
copd
exacerb
thu
confirm
relev
import
context
human
diseas
primari
rv
infect
model
fp
suppress
induct
type
type
iii
ifn
rv
delay
viru
clearanc
vivo
data
extend
observ
previou
studi
report
suppress
ifn
respons
viru
infect
associ
corticosteroid
administr
peripher
blood
mononuclear
cell
fibroblast
airway
epitheli
cell
intact
type
ifn
respons
import
effect
lung
viru
control
previous
report
mice
exhibit
increas
viru
load
infect
rv
addit
show
impair
ex
vivo
ifn
respons
patient
copd
experiment
infect
rv
increas
airway
viru
load
compar
control
without
airway
obstruct
therebi
indic
ifn
respons
also
import
determin
viru
control
man
find
fp
administr
mous
model
delay
viru
clearanc
vivo
support
human
studi
report
increas
viral
titr
associ
system
corticosteroid
administr
rv
challeng
healthi
subject
increas
rv
shed
intranas
fp
administr
natur
occur
cold
although
conflict
data
exist
anoth
studi
show
trend
toward
increas
viru
shed
follow
combin
treatment
oral
intranas
corticosteroid
experiment
rv
challeng
although
effect
size
observ
mous
model
rel
small
observ
delay
viru
clearanc
anim
model
limit
replic
occur
human
rv
infect
replic
robust
longer
durat
ic
may
expect
even
pronounc
effect
howev
acknowledg
mous
model
lung
rv
infect
accur
model
sustain
nasal
viral
replic
seen
man
restrict
viral
replic
mean
vivo
data
show
icsmedi
increas
viru
load
interpret
caution
conclus
evid
effect
ic
viru
replic
requir
use
ic
administr
experiment
viru
challeng
copd
patient
addit
identifi
compon
viral
rna
recognit
andor
ifnar
signal
pathway
disrupt
ic
use
vitro
method
specif
prractiv
viral
rna
surrog
experiment
approach
use
fp
administr
effect
isg
express
phosphoryl
follow
stimul
recombin
therebi
suggest
inhibitori
effect
fp
may
confin
initi
virussens
pathway
effect
autocrin
amplif
via
ifnar
previous
shown
induct
ifn
rv
infect
occur
initi
via
endosom
prr
later
via
induc
cytoplasm
helicas
rigi
current
studi
fp
suppress
ifn
express
suggest
corticosteroid
inhibit
ifn
product
occur
earli
effect
initi
endosom
sens
rv
keep
find
observ
fp
suppress
promot
activ
induc
trif
adaptor
molecul
utilis
stimul
type
ifn
express
addit
evalu
effect
fp
administr
stimul
airway
epitheli
cell
agonist
cytosol
prr
downstream
surprisingli
found
differenti
effect
suppress
rigiinduc
effect
ifn
express
addit
fp
suppress
promot
activ
induc
mav
adaptor
molecul
utilis
rigi
stimul
ifn
express
reason
discrep
effect
fp
pathway
mediat
cytoplasm
receptor
rigi
share
mani
similar
unclear
possibl
differ
exist
adaptor
molecul
mav
utilis
rigi
stimul
ifn
product
nonetheless
data
suggest
fp
may
exert
inhibitori
effect
ifn
induct
inhibit
virussens
pathway
consist
studi
report
fp
suppress
poli
c
induct
cell
howev
note
although
select
agonist
use
support
previou
studi
exclud
ligand
employ
studi
trigger
addit
prr
state
evid
ic
affect
ifn
signal
shown
mous
model
fp
administr
suppress
activ
lung
signal
intermedi
innat
respons
howev
note
nuclei
obtain
use
method
multipl
cell
type
possibl
data
may
explain
effect
ic
cellular
composit
adapt
immun
respons
import
viru
clearanc
prevent
reinfect
observ
fp
administr
prior
rv
infect
mice
led
suppress
cellular
adapt
respons
impair
product
rvspecif
igg
neutralis
antibodi
find
fp
impair
product
antibodi
respons
rv
infect
mous
model
suggest
use
commonli
prescrib
inhal
copd
exacerb
could
impair
natur
protect
respons
futur
rv
infect
thu
limit
longterm
efficaci
ic
reduct
exacerb
support
previou
studi
report
patient
exacerbationpron
copd
lower
rvspecif
antibodi
level
stabl
state
nonexacerb
patient
suggest
defici
humor
immun
respons
rv
might
import
determin
exacerb
risk
rv
induct
major
airway
mucin
also
enhanc
fp
administr
mous
model
impair
mucociliari
clearanc
mucu
hypersecret
featur
stabl
diseas
copd
like
contribut
airflow
limit
acceler
lung
function
declin
increas
morbid
addit
lung
overexpress
report
case
fatal
asthma
thu
associ
advers
outcom
rv
infect
stimul
mucu
product
airway
epithelium
therebi
potenti
sputum
product
acut
exacerb
find
fp
administr
diminish
control
rv
infect
lead
increas
mucin
express
suggest
use
therapi
may
worsen
mucu
hypersecret
lead
enhanc
andor
prolong
symptom
delay
recoveri
exacerb
administr
recombin
combin
fp
rv
infect
mice
reconstitut
suppress
innat
respons
improv
viru
clearanc
suggest
fp
suppress
ifn
respons
play
major
mechanist
role
advers
effect
viru
control
rvinfect
mice
given
steroid
treat
also
reduc
express
compar
fptreat
rvinfect
mice
support
hypothesi
suppress
ifn
underli
enhanc
product
associ
fp
administr
addit
observ
mice
diminish
product
type
ifn
respons
rv
infect
also
increas
bal
provid
evid
type
ifn
neg
regul
mucin
product
similar
observ
previous
report
mice
infect
cryptococcu
neoforman
associ
ic
pneumonia
risk
copd
first
report
confirm
numer
studi
base
perceiv
risk
clinician
question
uncrit
use
wide
prescrib
therapi
copd
ongo
evid
practic
chang
remark
underli
mechan
effect
never
identifi
previous
report
experiment
rv
challeng
induc
secondari
bacteri
infect
copd
virusinduc
suppress
amp
slpi
elafin
current
studi
addit
suppress
ifn
fp
also
suppress
rv
induct
number
airway
antibacteri
respons
includ
slpi
accompani
increas
bacteri
load
recombin
administr
revers
suppress
slpi
reduc
increas
bacteri
load
associ
fp
administr
without
affect
suppress
antibacteri
respons
combin
data
suggest
fp
may
potenti
increas
risk
virusinduc
secondari
bacteri
pneumonia
suppress
slpi
recombin
ifn
therapi
may
prevent
increas
bacteri
load
follow
rv
infect
specul
could
one
mechan
explain
increas
pneumonia
risk
associ
ic
use
copd
consist
previou
data
show
higher
rv
load
associ
increas
risk
secondari
bacteri
infect
copd
icsrel
pneumonia
episod
typic
follow
protract
symptomat
exacerb
studi
previous
suggest
corticosteroid
may
enhanc
slpi
product
bronchial
epithelium
vitro
studi
carri
model
stabl
rather
exacerb
diseas
conflict
data
exist
effect
corticosteroid
cell
type
monocyt
suppress
rather
enhanc
observ
viru
infect
clearli
demonstr
rang
model
fp
suppress
effect
airway
slpi
product
sinc
previous
shown
regul
slpi
express
fp
like
impair
slpi
product
rv
infect
suppress
prrinduc
ifn
product
therebi
reduc
subsequ
ifnarmedi
activ
mechan
support
find
mice
also
reduc
rv
induct
slpi
addit
evid
import
defici
slpi
import
mechan
bacteri
infect
copd
provid
studi
shown
reduc
airway
slpi
frequent
notabl
greater
proport
take
ic
versu
infrequ
copd
exacerb
patient
posit
bacteri
cultur
exacerb
collect
studi
use
recombin
ifn
administr
mice
rv
infect
mous
strain
identifi
ifn
central
regul
antibacteri
respons
mucu
product
rv
infect
clinic
trial
asthma
patient
take
ic
develop
cold
therapi
result
trend
toward
reduc
viru
load
clinic
benefit
patient
moderatesever
diseas
find
administr
mous
model
improv
viru
control
augment
antibacteri
immun
revers
enhanc
express
associ
fp
treatment
add
weight
potenti
benefit
inhal
interferon
treatment
virusinduc
exacerb
airway
diseas
thoma
et
al
report
administr
may
similarli
amelior
ic
impair
lung
influenza
viru
control
mice
although
inhal
therapi
clinic
develop
therefor
greatest
current
interest
inhal
previous
shown
safe
patient
asthma
dedic
studi
requir
investig
util
copd
note
overal
exacerb
reduct
associ
ic
use
copd
outweigh
potenti
risk
pneumonia
data
show
fp
suppress
virusinduc
airway
inflamm
support
benefici
effect
associ
use
therapi
plausibl
advers
effect
ic
hostdef
report
current
studi
might
occur
frequent
context
sever
infect
lead
unfavour
skew
riskbenefit
ratio
futur
develop
select
steroid
retain
potenti
benefici
antiinflammatori
effect
without
advers
effect
antivir
immun
could
provid
effect
approach
addit
confirm
advers
effect
fp
identifi
primari
infect
model
also
occur
model
copd
exacerb
evalu
whether
detriment
effect
occur
copd
import
copd
report
rel
steroidresist
diseas
therefor
feasibl
steroidinduc
advers
effect
may
observ
context
primari
copd
aec
fp
suppress
rv
induct
ifn
respons
also
enhanc
mucu
product
confirm
find
vivo
use
mous
model
copd
exacerb
similarli
demonstr
fp
suppress
rvinduc
ifn
respons
lead
delay
viru
clearanc
mucu
hypersecret
vivo
thu
fp
administr
vitro
vivo
copd
model
associ
suppress
ifn
respons
confirm
advers
effect
still
occur
steroidresist
diseas
model
increas
viru
load
mucu
product
observ
vivo
could
impact
advers
exacerb
sever
elastas
mous
model
copd
reproduc
mani
immunopatholog
featur
human
copd
exacerb
well
recognis
exist
model
complet
recapitul
complex
human
copd
occur
genet
suscept
individu
follow
prolong
cigarett
smoke
exposur
elastas
administr
repres
synthet
model
copd
anim
studi
use
altern
model
approach
smoke
exposur
genet
manipul
requir
confirm
find
confirm
direct
relev
find
use
ic
clinic
set
analysi
sputum
sampl
patient
copd
present
virusassoci
exacerb
ic
use
associ
suppress
ifn
respons
exacerb
concomit
increas
level
keep
find
mous
rv
infect
model
support
hypothesi
icsmedi
suppress
slpi
promot
increas
pneumonia
risk
copd
also
observ
suppress
sputum
slpi
mrna
increas
bacteri
load
ic
user
data
suggest
prior
vitro
vivo
mous
model
find
could
applic
context
human
copd
exacerb
provid
preliminari
clinic
evid
use
ic
may
advers
effect
use
exacerb
patient
studi
use
larger
number
copd
subject
need
confirm
data
neg
correl
interferon
respons
concentr
posit
correl
interferon
respons
slpi
express
also
observ
support
conclus
type
ifn
play
central
role
regul
mucu
secret
antimicrobi
immun
exacerb
summari
studi
demonstr
inhal
corticosteroid
use
suppress
antivir
immun
respons
accompani
advers
effect
mucin
product
antibacteri
immun
virusinduc
copd
exacerb
role
recombin
interferon
adjunct
therapi
negat
advers
effect
ic
copd
warrant
explor
schemat
represent
show
propos
advers
consequ
inhal
corticosteroid
use
exacerb
potenti
benefici
effect
interferon
therapi
shown
fig
futur
develop
novel
select
steroid
retain
benefici
antiinflammatori
effect
lack
advers
effect
antimicrobi
immun
mucin
product
could
effect
treatmentprevent
copd
exacerb
thu
greater
benefit
clinic
practic
cell
virus
cell
european
collect
cell
cultur
cultur
rpmi
medium
foetal
calf
serum
fc
rhinoviru
serotyp
propag
ohio
hela
cell
european
collect
cell
cultur
standard
method
inactiv
exposur
uv
light
mj
cm
min
vivo
use
mous
model
viru
purifi
use
precipit
polyethylen
glycol
sigmaaldrich
nacl
follow
filtrat
use
syring
filter
buffer
exchang
concentr
amicon
centrifug
filter
unit
kda
nomin
molecular
weight
limit
millipor
usa
viru
infect
treatment
fp
receptor
agonist
cell
cultur
confluenc
plate
cell
treat
nm
fluticason
propion
sigmaaldrich
diluent
alon
mock
h
cultur
subsequ
stimul
ml
moi
agonist
poli
c
invitrogen
ngml
agonist
transfect
poli
c
high
mw
form
specif
previous
describ
confluent
rhegf
concentr
chang
ngml
ali
phase
differenti
basal
compart
beneath
transwel
insert
without
apic
media
day
initi
seed
day
initi
seed
basal
media
replac
media
contain
nm
fluticason
propion
appropri
well
infect
moi
appli
apic
surfac
h
bebm
minim
infect
media
replac
fresh
bebm
minim
remaind
time
cours
sampl
collect
h
post
infect
time
point
apic
media
remov
cultur
store
protein
express
analys
half
transwel
membran
care
cut
insert
collect
rlt
buffer
qiagen
contain
downstream
molecular
analys
rtqpcr
remain
transwel
membran
fix
neutralbuff
formalin
h
histolog
crosssect
confirm
differenti
stain
period
acidschiff
pa
assess
mucu
product
rhinoviru
infect
treatment
mice
vivo
protocol
femal
mice
week
age
background
use
anim
studi
mice
purchas
charl
river
laboratori
hous
individu
ventil
cage
specif
pathogenfre
condit
anim
work
perform
author
uk
home
offic
outlin
anim
scientif
procedur
act
ethic
review
imperi
colleg
london
anim
welfar
ethic
review
bodi
project
licenc
ppl
fp
powder
sigmaaldrich
resuspend
concentr
dimethyl
sulfoxid
dmso
sigmaaldrich
dilut
pb
mice
treat
intranas
light
isofluran
anaesthesia
fp
solut
equat
fp
dose
vehicl
dmso
dilut
pb
control
one
hour
fp
vehicl
administr
mice
infect
intranas
tcid
uvinactiv
control
detail
separ
experi
h
follow
challeng
mice
addit
treat
intranas
pb
contain
unit
recombin
r
system
fluticason
administr
copd
exacerb
mous
model
mice
treat
intranas
light
isofluran
anaesthesia
unit
porcin
pancreat
elastas
merck
induc
emphysemat
lung
chang
ten
day
follow
elastas
administr
mice
treat
intranas
fp
solut
prepar
detail
h
prior
intranas
infect
tcid
dose
reduct
primari
rv
infect
model
uvinactiv
control
detail
natur
occur
human
copd
exacerb
cohort
cohort
copd
subject
recruit
studi
investig
natur
occur
exacerb
june
decemb
subject
grade
copd
sever
confirm
spirometri
recruit
treatment
permit
subject
gave
inform
written
consent
studi
protocol
approv
east
london
research
ethic
committe
protocol
number
subject
initi
baselin
visit
clinic
stabil
medic
assess
peak
expiratori
flow
rate
measur
spirometri
forc
expiratori
volum
forc
vital
capac
fvc
clinic
sampl
collect
sputum
induct
process
sputum
induc
use
premed
salbutamol
via
meter
dose
inhal
larg
volum
spacer
four
per
cent
salin
administ
use
devilbiss
ultrason
nebulis
adequ
sputum
sampl
obtain
sputum
process
within
h
induct
sputum
plug
select
saliva
macroscop
inspect
sampl
aliquot
select
store
unprocess
remain
sampl
weigh
dithiothreitol
dtt
ad
ratio
ml
dtt
g
sputum
mixtur
agit
filter
volum
pb
ad
filtrat
centrifug
supernat
aliquot
store
viru
detect
virus
detect
sputum
use
polymeras
chain
reaction
follow
virus
investig
adenoviru
coronaviru
human
bocaviru
human
metapneumoviru
influenza
b
parainfluenza
picornaviru
respiratori
syncyti
viru
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
picornavirus
rna
convert
cdna
addit
reaction
mix
contain
invitrogen
dtt
dntp
invitrogen
revers
transcriptas
invitrogen
singl
round
pcr
cycl
use
detect
picornavirus
cdna
differenti
rv
enterovirus
achiev
restrict
enzym
digest
pcr
product
virus
convers
cdna
achiev
rna
ad
reaction
mix
contain
random
hexam
primer
promega
uhq
nucleasefre
water
promega
mixtur
denatur
min
quench
ice
firststrand
buffer
uhq
dtt
dntp
revers
transcriptas
qiagen
ad
follow
incub
h
yield
cdna
aliquot
cdna
use
rtpcr
panel
perform
use
thermal
cycler
appli
biosystem
followup
subject
repeat
visit
three
monthli
interv
clinic
stabl
follow
minimum
month
subject
report
studi
team
develop
symptom
acut
exacerb
defin
use
east
london
cohort
criteria
seen
within
h
symptom
onset
sputum
sampl
collect
onset
exacerb
week
exacerb
cell
assay
mous
model
bal
perform
cannul
trachea
lavag
ml
steril
pb
cell
pellet
centrifug
resuspend
ack
buffer
lyse
red
cell
wash
pb
resuspend
rpmi
medium
fb
cell
stain
quik
diff
reagena
differenti
count
flow
cytometri
analysi
lung
leukocyt
obtain
bal
red
cell
lyse
ack
buffer
bal
cell
stain
livedead
fixabl
dead
cell
stain
life
technolog
carlsbad
ca
incub
antimous
fc
block
bd
bioscienc
subsequ
directli
fluorochromeconjug
monoclon
antibodi
specif
clone
bd
bioscienc
clone
bd
bioscienc
clone
bd
bioscienc
clone
bd
bioscienc
clone
bd
bioscienc
data
acquir
lsr
ii
flow
cytomet
bd
bioscienc
analys
use
flowjo
softwar
version
tree
star
ashland
usa
repres
gate
strategi
use
analysi
cell
surfac
stain
shown
supplementari
fig
protein
assay
cytokin
protein
level
mous
bal
human
sputum
supernat
cell
supernat
vitro
experi
assay
use
commerci
duoset
enzymelink
immunosorb
assay
kit
r
system
abingdon
uk
protein
bal
measur
adhes
plate
allow
sampl
evapor
overnight
plate
wash
three
time
step
plate
block
h
bovin
serum
albumin
bsa
phosphatebuff
salin
measur
detect
antibodi
use
biotinyl
thermo
scientif
ngml
assay
detect
antibodi
mous
clone
bound
antibodi
detect
peroxidaseconjug
goat
antimous
igg
sigmaaldrich
standard
curv
mucin
elisa
gener
serial
dilut
supernat
taken
ionomycinstimul
cell
bal
supernat
previous
taken
ovalbumininduc
hyperallerg
mice
western
blot
use
evalu
protein
cell
extract
cell
lyse
radioimmunoprecipit
ripa
buffer
sigmaaldrich
supplement
proteas
roch
phosphatas
inhibitor
sigmaaldrich
protein
content
measur
bicinchonin
acid
assay
thermo
scientif
equal
amount
protein
load
onto
bistri
sdspage
gel
transfer
onto
polyvinyliden
difluorid
pvdf
membran
life
technolog
membran
block
bsa
trisbuff
salin
h
room
temperatur
follow
primari
antibodi
use
rabbit
dilut
new
england
biolab
new
england
biolab
dilut
new
england
biolab
dilut
new
england
biolab
primari
antibodi
incub
overnight
shake
secondari
antibodi
conjug
horseradish
peroxidas
dilut
jackson
immunoresearch
incub
h
room
temperatur
data
acquir
use
fusion
imag
analys
vilber
lourmat
uncrop
western
blot
imag
shown
supplementari
fig
measur
serum
antibodi
mous
model
peripher
blood
collect
carotid
arteri
serum
rvspecif
igg
measur
inhous
enzymelink
immunosorb
assay
ninetysixwel
plate
coat
purifi
use
vivo
infect
incub
overnight
plate
block
milk
tween
room
temperatur
aliquot
per
well
serum
dilut
milkpb
ad
h
incub
room
temperatur
igg
detect
antibodi
biotinyl
rat
antimous
clone
bd
bioscienc
clone
bd
bioscienc
prepar
lung
nuclear
extract
measur
transcript
factor
activ
left
lung
excis
immedi
place
ml
tube
snap
frozen
liquid
nitrogen
follow
storag
lung
tissu
manual
homogenis
immers
liquid
nitrogen
use
mortar
pestl
nuclear
extract
prepar
use
nuclear
extract
kit
activ
motif
la
hulp
belgium
activ
transcript
factor
gr
subunit
assess
mous
lung
tissu
use
commerci
avail
dna
bind
assay
activ
motif
use
per
well
nuclear
protein
neutralis
assay
neutralis
rv
measur
ohio
hela
cell
uk
health
protect
agenc
gener
cell
collect
grown
confluent
plate
pool
sera
given
treatment
group
incub
purifi
medium
control
room
temperatur
shake
h
ad
hela
cell
incub
h
protect
cytopath
effect
measur
crystal
violet
cell
viabil
assay
cell
stain
wv
crystal
violet
sigmaaldrich
room
temperatur
min
cell
wash
water
airdri
crystal
violet
solubilis
sodium
dodecyl
sulphat
sd
solut
wv
absorb
measur
spectramax
plu
plate
reader
nm
rna
extract
cdna
synthesi
quantit
pcr
total
rna
extract
primari
airway
epitheli
cell
sputum
cell
rneasi
kit
qiagen
use
cdna
synthesi
omniscript
rt
kit
mous
model
total
rna
extract
right
upper
lobe
mous
lung
place
rna
later
prior
rna
extract
cdna
synthesi
detail
quantit
pcr
carri
use
previous
describ
specif
primer
probe
gene
interest
normalis
rrna
reaction
analys
use
abi
fast
realtim
pcr
system
appli
biosystem
carlsbad
ca
dna
extract
bacteri
quantit
pcr
dna
extract
human
sputum
mous
lung
tissu
perform
use
fastdna
spin
kit
soil
mp
biomed
santa
ana
usa
per
manufactur
instruct
beadbeat
perform
two
cycl
rpm
precelli
bertin
technolog
total
bacteri
load
measur
use
quantit
pcr
perform
triplic
use
realtim
pcr
system
life
technolog
addit
templat
pcr
reaction
mix
contain
forward
primer
revers
primer
sybr
fast
univers
master
mix
kapa
biosystem
h
pcr
cycl
condit
cycl
min
follow
cycl
melt
condit
cycl
cycl
min
follow
dissoci
creation
standard
curv
dilut
seri
copi
partial
rrna
gene
vibrio
natriegen
dsmz
deutsch
sammlung
von
mikroorganismen
braunschweig
germani
posit
escherichia
coli
refer
clone
use
topo
ta
clone
kit
invitrogen
thermofish
scientif
use
statist
analys
mous
experi
anim
studi
group
size
fiveeight
mice
per
experiment
condit
data
present
mean
sem
repres
least
two
combin
independ
experi
data
analys
use
oneor
twoway
anova
signific
differ
group
assess
bonferroni
multipl
comparison
test
vitro
experi
perform
threefiv
time
data
express
mean
sem
data
analys
oneor
twoway
anova
test
differ
group
assess
bonferroni
multipl
comparison
test
vitro
primari
airway
epitheli
cell
experi
perform
group
size
n
patient
individu
data
point
shown
data
analys
use
oneway
anova
signific
differ
group
assess
bonferroni
multipl
comparison
test
data
human
copd
cohort
analys
use
mannwhitney
utest
kruskalw
test
dunn
post
test
compar
protein
level
mrna
express
ic
user
nonus
correl
data
set
examin
use
spearman
rank
correl
coeffici
statist
perform
use
graphpad
prism
softwar
differ
consid
signific
p
data
avail
data
support
find
studi
avail
articl
supplementari
inform
file
correspond
author
request
receiv
septemb
accept
may
